 |
Diseases |  |
Trials |
|
Trials |  |
News |  |
| 12345678910» |
- | Journal: Mutant prevention concentrations and phenotypic and genomic profiling of first-step resistance mechanisms to classical and novel ?-lactams in Pseudomonas aeruginosa. (Pubmed Central) - Mar 12, 2025
This work first describes the MPCs and first-step resistance mechanisms for classical and novel ?-lactams in P. aeruginosa. The identified shared and differential resistance development patterns between the available classical and novel ?-lactams should be helpful to guide treatment strategies for XDR P. aeruginosa infections.
- | Zerbaxa (ceftolozane /tazobactam) / Merck (MSD), imipenem/relebactam / Merck (MSD)
Journal: Tazobactam/Ceftolozane (TAZ/CTLZ) and Relebactam/Imipenem (REL/IPM) susceptibility in Japan: nationwide surveillance of respiratory bacterial pathogens in 2019/20. (Pubmed Central) - Mar 9, 2025
The identified shared and differential resistance development patterns between the available classical and novel ?-lactams should be helpful to guide treatment strategies for XDR P. aeruginosa infections. Susceptible rates for P. aeruginosa to IPM, ceftazidime (CAZ), and levofloxacin (LVFX) were 84.1, 87.8, and 76.8
- | Journal: New Kids on the Block: Estimating Use of Next-generation Gram-negative Antibiotics Across Greater Than 700 Hospitals in the United States. (Pubmed Central) - Mar 5, 2025
In recent years, new broad-spectrum antibiotics targeting Gram-negative organisms have been introduced, including cefiderocol, ceftazidime-avibactam, ceftolozane-tazobactam, eravacycline, imipenem-relebactam, omadacycline, and meropenem-vaborbactam...In contrast, piperacillin-tazobactam was prescribed in 731 719 (18.8%) and colistin in 570 (0.01%) admissions...Ceftazidime-avibactam and ceftolozane-tazobactam remain the most frequently prescribed new antibiotics, with uptake of subsequently approved agents trailing. New antibiotics are most commonly used as treatment for sepsis among patients with multiple comorbidities.
- | Fetroja (cefiderocol) / Shionogi
Preclinical, Journal: In-vitro activity of the novel ?-lactam/?-lactamase inhibitor combinations and cefiderocol against carbapenem-resistant Pseudomonas spp. clinical isolates collected in Switzerland in 2022. (Pubmed Central) - Mar 4, 2025
FDC exhibited an excellent in-vitro activity against this collection of CRP recovered from Switzerland in 2022, including MBL producers. The new BL/BLI combinations displayed significant activity against non-carbapenemase CRP, with IPR and C/T showing the highest susceptibility rates.
- | Journal: Comparative phenotypic and genotypic antimicrobial susceptibility surveillance in Achromobacter spp. through whole genome sequencing. (Pubmed Central) - Feb 27, 2025
In general, the species other than A. xylosoxidans showed lower MIC50 and MIC90, especially to carbapenems and ?-lactamase inhibitor combinations like piperacillin-tazobactam, meropenem-vaborbactam, and imipenem-relebactam...Our study provides phenotypic data regarding identification and susceptibility testing and correlates this with the genotypic characterization of 109 clinical isolates belonging to Achromobacter spp. This comprehensive study sheds light on the phenotypic and genotypic character of this bacteria, that is of increasing clinical relevance in hospital-acquired infections.
- | imipenem/relebactam / Merck (MSD), Fetroja (cefiderocol) / Shionogi
Journal: Combating Metallo-?-Lactamase-Producing Pseudomonas aeruginosa: The Fractional Inhibitory Concentration Index as a Tool to Evaluate Antibiotic Synergy. (Pubmed Central) - Feb 26, 2025
Cefiderocol in association with imipenem-relebactam exhibited a synergistic effect against IMP-producing P. aeruginosa isolates. Further studies with a range of drugs and an expanded number of isolates are required to ascertain potential novel synergistic associations and the clinical utility of the fractional inhibitory concentration index.
- || Review, Journal: Difficult-to-Treat Pseudomonas aeruginosa Infections in Critically Ill Patients: A Comprehensive Review and Treatment Proposal. (Pubmed Central) - Feb 26, 2025
In this review, we examine the epidemiology, resistance mechanisms, risk factors, and available and future therapeutic options, as well as strategies for treatment optimization. Finally, we propose a treatment algorithm to facilitate decision making based on the resistance patterns specific to each Intensive Care Unit.
- | Preclinical, Journal: In vitro activity of ceftazidime-avibactam, ceftolozane-tazobactam, imipenem-relebactam, meropenem-vaborbactam and cefiderocol against carbapenemase-producing Enterobacterales from clinical isolates in a (Pubmed Central) - Feb 19, 2025
Finally, we propose a treatment algorithm to facilitate decision making based on the resistance patterns specific to each Intensive Care Unit. Cefiderocol appears to be the most effective
- | imipenem/relebactam / Merck (MSD), Vabomere (meropenem/vaborbactam) / Melinta Therap, Menarini, Zavicefta (ceftazidime/avibactam) / Pfizer, AbbVie
Observational data, Preclinical, Journal: In vitro activity and genomic characterization of KPC-producing Klebsiella pneumoniae clinical blood culture isolates resistant to ceftazidime/avibactam, meropenem/vaborbactam, imipenem/relebactam: an Italian nationwide multicentre observational study (2022-23). (Pubmed Central) - Feb 2, 2025
New BLICs were shown to be the most widely active therapeutic option against KPC-Kp clinical isolates collected in Italy. Ceftazidime/avibactam resistance is mainly driven by the expression of KPC variants, whereas the loss of function of the OmpK35 and OmpK36 porins appears to play a key but not exclusive role in the development of meropenem/vaborbactam and/or imipenem/relebactam resistance.
- | Journal: Antimicrobial activity of imipenem/relebactam and comparator agents against Gram-negative isolates collected from pediatric patients: SMART 2018-2022 Global Surveillance. (Pubmed Central) - Jan 12, 2025
Ceftazidime/avibactam resistance is mainly driven by the expression of KPC variants, whereas the loss of function of the OmpK35 and OmpK36 porins appears to play a key but not exclusive role in the development of meropenem/vaborbactam and/or imipenem/relebactam resistance. Based on in vitro data, IMI/REL represents a good therapeutic option for most hospitalized pediatric patients infected with common Gram-negative pathogens.
- | Preclinical, Journal: Detection of carbapenemases in Enterobacterales susceptible in vitro to meropenem. (Pubmed Central) - Jan 12, 2025
Based on in vitro data, IMI/REL represents a good therapeutic option for most hospitalized pediatric patients infected with common Gram-negative pathogens. We highlight the importance of tracking carbapenemases for epidemiological control and therapeutic guidance.
- | imipenem/relebactam / Merck (MSD)
Journal: Mobilization of an ICEclc-like element as a potential mechanism for the spread of IMP-13 carbapenemase in Pseudomonas aeruginosa. (Pubmed Central) - Dec 21, 2024
Additionally, three of the studied isolates exhibited high-level resistance to imipenem and imipenem-relebactam that was linked to an insertion sequence in the oprD gene...The conjugation rate was low, at approximately 10-8 transconjugants per donor and ICE transfer appeared to mobilize some adjacent parental genes located immediately downstream of the ICE. In conclusion, these results suggest that even if the spread of blaIMP-13 is mainly due to an epidemic ST621 clone, the mobilization of a blaIMP-13-carrying ICEclc-like element is possible and should not be underestimated.
- | imipenem/relebactam / Merck (MSD), Vabomere (meropenem/vaborbactam) / Melinta Therap, Menarini
Journal: NDM-1 and KPC-3 co-producing Klebsiella pneumoniae ST512 in bronchial secretion from a patient in an intensive care unit of a Greek Tertiary Care Hospital. (Pubmed Central) - Dec 19, 2024
In conclusion, these results suggest that even if the spread of blaIMP-13 is mainly due to an epidemic ST621 clone, the mobilization of a blaIMP-13-carrying ICEclc-like element is possible and should not be underestimated. The strain was resistant to all beta-lactams, including combinations with
- | Journal, Gram negative: [Translated article] National survey and consensus document on dosing strategies for beta-lactam antibiotics against multidrug-resistant gram-negative bacilli (MDR-GNB) in critically ill patients undergoing extracorporeal life-support techniques: The DOSEBL study protocol. (Pubmed Central) - Dec 16, 2024
The availability of extracorporeal life-support techniques has expanded significantly in recent years, alongside a rise in the prevalence of infections caused by MDR-GNB. There is a need to develop evidence-based tools of high quality to standardize dosing and monitoring strategies for new ?-lactam antibiotics.
- | imipenem/relebactam / Merck (MSD), Zavicefta (ceftazidime/avibactam) / Pfizer, AbbVie
Preclinical, Journal: Mutant prevention concentrations, in vitro resistance evolution dynamics, and mechanisms of resistance to imipenem and imipenem/relebactam in carbapenem-susceptible Klebsiella pneumoniae isolates showing ceftazidime/avibactam resistance. (Pubmed Central) - Dec 5, 2024
Genetic and biochemical characterization of the KPC derivatives identified in the resistant mutants confirmed their role in carbapenem resistance. Our data positions imipenem/relebactam as an attractive therapeutic option for combating ceftazidime/avibactam-resistant KPC-producing K. pneumoniae infections.
- | KSP-1007 / Sumitomo Pharma, The Kitasato Institute
Preclinical, Journal, Combination therapy, Gram negative: In vitro and in vivo activities of KSP-1007, a broad-spectrum inhibitor of serine- and metallo-?-lactamases, in combination with meropenem against carbapenem-resistant Gram-negative bacteria. (Pubmed Central) - Dec 5, 2024
Our data positions imipenem/relebactam as an attractive therapeutic option for combating ceftazidime/avibactam-resistant KPC-producing K. pneumoniae infections. The MIC90 of MEM/KSP-1007 at 8
- | imipenem/relebactam / Merck (MSD)
Journal, Real-world evidence, Real-world: Real-World Experience of Imipenem-Relebactam Treatment as Salvage Therapy in Difficult-to-Treat Pseudomonas aeruginosa Infections (IMRECOR Study). (Pubmed Central) - Nov 29, 2024
Imipenem/cilastatin/relebactam may represent a treatment option for patients with DTR-P. aeruginosa infections, which should be validated in prospective clinical trials.
- | imipenem/relebactam / Merck (MSD), Vabomere (meropenem/vaborbactam) / Melinta Therap, Menarini, Xerava (eravacycline) / SOM Biotech, Ewha Womans University, PAION, Innoviva
Journal, Gram negative: Colistin, Meropenem-Vaborbactam, Imipenem-Relebactam, and Eravacycline Testing in Carbapenem-Resistant Gram-Negative Rods: A Comparative Evaluation of Broth Microdilution, Gradient Test, and VITEK 2. (Pubmed Central) - Nov 27, 2024
VITEK 2 was mostly accurate in measuring ERV MICs, while the corresponding gradient test yielded reliable results exclusively in CREs. It is essential that laboratories are aware of which testing method provides reliable results for each combination of microorganisms and reserve antibiotics.
- | cefepime/zidebactam IV (WCK 5222) / Wockhardt
Preclinical, Journal: In vitro activity of zidebactam/cefepime (WCK 5222), a ?-lactam enhancer/ ?-lactam combination against carbapenem- and colistin-resistant Klebsiella pneumoniae isolates. (Pubmed Central) - Nov 24, 2024
Zidebactam/cefepime combination was highly active against multi-clonal, carbapenem-non-susceptible and colistin-resistant K. pneumoniae isolates producing OXA-48-like (Ambler class D) or/and NDM (Ambler class B) carbapenemases, thus potentially offering a valuable treatment options for infections caused by such pan-drug resistant resistotypes. Though, zidebactam is not an inhibitor of class B and D ?-lactamases, potent activity of zidebactam/cefepime combination is attributable to ?-lactam enhancer mechanism.
- | relebactam (MK-7655) / Merck (MSD)
Journal: Eco-Friendly Synchronous Spectrofluorimetric Determination of Imipenem, Cilastatin, and Relebactam; Application to Market Formulations and Biological Fluids; Greenness Assessment. (Pubmed Central) - Nov 17, 2024
Though, zidebactam is not an inhibitor of class B and D ?-lactamases, potent activity of zidebactam/cefepime combination is attributable to ?-lactam enhancer mechanism. Fourier Self-Deconvolution was subsequently applied to the spectrum to estimate relebactam and imipenem at 430
- | imipenem/relebactam / Merck (MSD)
Journal: Discovery of sulfone containing metallo-?-lactamase inhibitors with reduced bacterial cell efflux and histamine release issues. (Pubmed Central) - Nov 16, 2024
The novel derivatives were overall more effective in gram-negative bacterial cell-based assays when combined with imipenem and relebactam. The major contributors to the improved anti-bacterial activity are enhanced enzyme-inhibitor interactions and reduced bacterial cell efflux monitored via an efflux assay involving isogenic Pseudomonas aeruginosa efflux?+?and efflux - tool strains.
- | Zavicefta (ceftazidime/avibactam) / Pfizer, AbbVie
Preclinical, Journal: In vivo divergent evolution of cross-resistance to new ?-lactam/?-lactamase inhibitor combinations in Pseudomonas aeruginosa following ceftazidime/avibactam treatment. (Pubmed Central) - Nov 15, 2024
Divergent resistance evolution resulted in a complex phenotype in the CRPA lineage, posing significant challenge to clinical treatment. The resistance surveillance needs to be prioritized, and new therapeutic strategies are urgently required.
- | Fetroja (cefiderocol) / Shionogi
Preclinical, Journal: In vitro activity assessment of cefiderocol against Enterobacterales, Pseudomonas aeruginosa, and Acinetobacter spp., including ?-lactam nonsusceptible molecularly characterized isolates, collected from 2020 to 2021 in the United States and European hospitals. (Pubmed Central) - Nov 7, 2024
To meet this need, this study phenotypically and genotypically characterized priority Gram-negative pathogens collected from patients in US and European hospitals to examine the activity of cefiderocol and other currently available treatment options, including carbapenems and ?-lactam-?-lactamase inhibitor combinations. The results presented here provide a detailed perspective to healthcare practitioners of cefiderocol's broad applicability, manifested in high activity and low nonsusceptibility rates, across phenotypic and genotypic organism groups relative to other agents and further support its use against the most intransigent infections.
- | Journal: Antimicrobial susceptibility to last-resort antibiotics in carbapenemase-producing bacteria from Ukrainian patients. (Pubmed Central) - Nov 7, 2024
For most CPE, a low minimal inhibitory concentration (MIC) of <0.5 mg/L was measured for tigecycline and ceftazidime-avibactam-aztreonam...For CRAB, ampicillin-sulbactam MICs were ?128 mg/L; for sulbactam-durlobactam, 1-2 mg/L...Our research revealed that there was extensive phenotypic resistance to last-resort antibiotics. Healthcare professionals should be aware of multidrug-resistant microorganisms when treating patients recently admitted in Ukraine, suspected for Gram-negative bacterial infection.
- | imipenem/relebactam / Merck (MSD)
Journal: AmpC induction by imipenem in Pseudomonas aeruginosa occurs in the absence of OprD and impacts imipenem/relebactam susceptibility. (Pubmed Central) - Nov 7, 2024
The data presented support the use of an alternative porin(s) for entry of imipenem. This study provides the basis for further investigation into modifications of imipenem or similar molecules that would increase the affinity for other porins in isolates resistant to imipenem.
- | Zavicefta (ceftazidime/avibactam) / Pfizer, AbbVie
Preclinical, Journal: Mechanisms leading to in vivo ceftazidime/avibactam resistance development during treatment of GES-5-producing Pseudomonas aeruginosa infections. (Pubmed Central) - Nov 6, 2024
Moreover, these mutations were associated with increased cefiderocol MICs but reduced carbapenem, particularly imipenem/relebactam, resistance. Understanding the complexity of resistance mechanisms to the growing repertoire of antipseudomonal ?-lactams is crucial to guide optimized treatments and antimicrobial stewardship measures.
- | Journal: Assessment of the activity and mechanisms of resistance to cefiderocol and combinations of ?-lactams and the novel ?-lactamase inhibitors avibactam, taniborbactam, zidebactam, nacubactam, xeruborbactam, and ANT3310 in emerging double-carbapenemase-producing Enterobacterales. (Pubmed Central) - Nov 6, 2024
Meropenem/ANT3310 (MIC50/MIC90 = 0.5/?64 mg/L; 47/57 susceptible) and cefepime/taniborbactam (MIC50/MIC90 = 0.5/16 mg/L; 44/57 susceptible) also retained high levels of activity, although they were affected by NDM-type enzymes in combination with porin deficiency. Our findings highlight that cefiderocol and combinations of ?-lactams and the novel ?-lactamase inhibitors avibactam, nacubactam, taniborbactam, zidebactam, xeruborbactam, and ANT3310 show promising activity against double-carbapenemase-producing Enterobacterales.
- | imipenem/relebactam / Merck (MSD)
Journal: Rapid detection of imipenem/relebactam susceptibility/resistance in Pseudomonas aeruginosa. (Pubmed Central) - Nov 2, 2024
The Rapid IPR Pseudomonas NP test is sensitive, specific, and easy to perform and interpret. Therefore, it is suitable for implementation in routine clinical laboratories.
- || Zerbaxa (ceftolozane /tazobactam) / Merck (MSD), imipenem/relebactam / Merck (MSD), Zavicefta (ceftazidime/avibactam) / Pfizer, AbbVie
Review, Journal: Insights into the Rising Threat of Carbapenem-Resistant Enterobacterales and Pseudomonas aeruginosa Epidemic Infections in Eastern Europe: A Systematic Literature Review. (Pubmed Central) - Oct 25, 2024
At the same time, it shows the activity of the standard of care and new antimicrobials against carbapenem-resistant Gram-negative pathogens in Eastern Europe. Clinical real-world data on the treatment of carbapenem-resistant infections in Eastern Europe are needed.
- | imipenem/relebactam / Merck (MSD), Vabomere (meropenem/vaborbactam) / Melinta Therap, Menarini
Journal: Therapeutic drug monitoring (TDM) of ?-lactam/?-lactamase inhibitor (BL/BLI) drug combinations: insights from a pharmacometric simulation study. (Pubmed Central) - Oct 22, 2024
This study highlights the risk of solely relying on TDM of BLs, as this can indicate acceptable exposures of the BL while the BLI concentration, and consequently the combination, can result in suboptimal performance in terms of bacterial killing. Thus, dose adjustments also based on plasma concentration measurements of BLIs, in particular for avibactam and tazobactam, can be valuable in clinical practice to obtain effective exposures at the target site.
- | Fetroja (cefiderocol) / Shionogi
Journal: Impact of chromosomally encoded resistance mechanisms and transferable ?-lactamases on the activity of cefiderocol and innovative ?-lactam/?-lactamase inhibitor combinations against Pseudomonas aeruginosa. (Pubmed Central) - Sep 30, 2024
However, the combined effects of efflux pumps, OprD deficiency and efficient ?-lactamases could still result in the loss of all therapeutic options. Resistance surveillance, judicious use of new agents and continued drug development efforts are encouraged.
- | Zerbaxa (ceftolozane /tazobactam) / Merck (MSD), imipenem/relebactam / Merck (MSD)
Journal, Gram negative: Susceptibility of Gram-negative pathogens collected in Israel to ceftolozane/tazobactam, imipenem/relebactam and comparators: SMART 2018-22. (Pubmed Central) - Sep 20, 2024
Most of the imipenem/relebactam- and ceftolozane/tazobactam-resistant P. aeruginosa characterized did not possess acquired ?-lactamases. Recent clinical isolates of Enterobacterales and P. aeruginosa collected in Israel were highly susceptible to ceftolozane/tazobactam and imipenem/relebactam.
- | Journal, Gram negative: National Survey and consensus document on dosing strategies for beta-lactam antibiotics against multidrug-resistant gram-negative bacilli (MDR-GNB) in critically ill patients undergoing extracorporeal life support techniques: The DOSEBL study protocol. (Pubmed Central) - Sep 20, 2024
The availability of extracorporeal life support techniques has expanded significantly in recent years, alongside a rise in the prevalence of infections caused by multidrug-resistant gram-negative bacilli (MDR-GNB). There is a need to develop evidence-based tools of high quality to standardize dosing and monitoring strategies for new ?-lactam antibiotics.
- | Journal: Occurrence of multi-carbapenemase-producing Enterobacterales in a tertiary hospital in Madrid (Spain): a new epidemiologic scenario. (Pubmed Central) - Sep 12, 2024
M-CPE is an emerging threat in our hospital. Co-production of different carbapenemases, including metallo-?-lactamases, limits therapeutic options and depicts the need to reinforce infection control measures.
- || imipenem/relebactam / Merck (MSD), Vabomere (meropenem/vaborbactam) / Melinta Therap, Menarini, Zavicefta (ceftazidime/avibactam) / Pfizer, AbbVie
Clinical, Journal: Susceptibility evaluation of novel beta-lactam/beta-lactamase inhibitor combinations against carbapenem-resistant Klebsiella pneumoniae from bloodstream infections in hospitalized patients in Brazil. (Pubmed Central) - Sep 12, 2024
This study demonstrated that, although high susceptibility rates to the BLBLI were found, KPC-2 isolates can also demonstrate resistance due to porin mutations. Additionally, NDM-1 isolates can demonstrate susceptibility in vitro to the BLBLI.
- | Fetroja (cefiderocol) / Shionogi
Preclinical, Journal, Gram negative: In vitro activity of cefiderocol against carbapenemase-producing and meropenem-non-susceptible gram-negative bacteria collected in the Japan Antimicrobial Resistant Bacterial Surveillance. (Pubmed Central) - Sep 12, 2024
Additionally, NDM-1 isolates can demonstrate susceptibility in vitro to the BLBLI. This is the first large-scale study to systematically demonstrate the efficacy of CFDC against IMP-type carbapenemase-producing strains with known genomic backgrounds.
- | imipenem/relebactam / Merck (MSD), Nuzyra (omadacycline) / Paratek
Journal: Clinical characteristics and antimicrobial susceptibility profiles of Mycobacterium abscessus and Mycobacterium massiliense pulmonary infection. (Pubmed Central) - Sep 12, 2024
Patients with M.ab-PD have complex underlying diseases and broader lobar lesions. IMP-REL and omadacycline are promising antibiotics for MABC infection treatment.
- | imipenem/relebactam / Merck (MSD), Vabomere (meropenem/vaborbactam) / Melinta Therap, Menarini, Zavicefta (ceftazidime/avibactam) / Pfizer, AbbVie
Preclinical, Journal, Combination therapy: In vitro Synergistic and Bactericidal Effects of Aztreonam in Combination with Ceftazidime/ Avibactam, Meropenem/Vaborbactam and Imipenem/Relebactam Against Dual-Carbapenemase-Producing Enterobacterales. (Pubmed Central) - Sep 9, 2024
Dual-carbapenemase-producing Enterobacterales posed a significant threat to clinical anti-infection treatment. However, the combination of ATM with innovative ?-lactam/?-lactamase inhibitor compounds had proven to be an effective treatment option.
- Emblaveo (aztreonam/avibactam) / Pfizer, AbbVie, imipenem/relebactam / Merck (MSD), Zavicefta (ceftazidime/avibactam) / Pfizer, AbbVie
Activity of ?-lactams and new ?-lactamase inhibitors in multidrug-resistant Burkholderia contaminans () - Sep 4, 2024 - Abstract #NACFC2024NACFC_835;
Although the presence of class D ?-L could contribute, our research suggests that other resistance mechanisms would also be involved. Studies with larger numbers of isolates are needed to validate these results and to establish valid breakpoints for B. contaminans.
- imipenem/relebactam / Merck (MSD)
Susceptibility of Clinical Non-Morganellaceae Enterobacterales Isolates from Bloodstream and Respiratory Tract Infections to Imipenem/Relebactam and Comparators: SMART United States 2020-2022 (Halls JK) - Sep 4, 2024 - Abstract #IDWeek2024IDWEEK_3255;
- Addition of Relebactam Increases Susceptibility to Imipenem Among Imipenem-Intermediate Pseudomonas aeruginosa: Asia/Pacific SMART 2018-2022 (Halls JK) - Sep 4, 2024 - Abstract #IDWeek2024IDWEEK_3248;
- imipenem/relebactam / Merck (MSD)
Partnering Imipenem/Relebactam (I/R) with Fosfomycin (FOS): Restoring Susceptibility Against Multi-Drug-Resistant Pseudomonas aeruginosa (Halls JK) - Sep 4, 2024 - Abstract #IDWeek2024IDWEEK_3239;
- Zerbaxa (ceftolozane /tazobactam) / Merck (MSD), imipenem/relebactam / Merck (MSD)
Activity of Ceftolozane/Tazobactam, Imipenem/Relebactam and Comparators Against Clinical MDR and DTR non-Morganellaceae Enterobacterales and Pseudomonas aeruginosa Stratified by Patient Age and Hospital Ward: SMART United States 2020-2022 (Halls JK) - Sep 4, 2024 - Abstract #IDWeek2024IDWEEK_3237;
- Fetroja (cefiderocol) / Shionogi
Evaluation of Phenotypic Cross-Resistance between Cefiderocol and ?-lactam/?-lactamase inhibitor combinations against Pseudomonas aeruginosa isolates from US Medical Centers (Halls JK) - Sep 4, 2024 - Abstract #IDWeek2024IDWEEK_3236;
- Fetroja (cefiderocol) / Shionogi
In vitro Activity of Cefiderocol and Comparator Agents Against Global Enterobacterales Isolates From Hospitalized Patients with Pneumonia Collected as Part of the SENTRY Surveillance Program (2020-2022) (Halls JK) - Sep 4, 2024 - Abstract #IDWeek2024IDWEEK_2958;
- Trends in Carbapenemase and Co-carbapenemase Production among Enterobacterales in Latin America: SMART 2018-2022 (Halls JK) - Sep 4, 2024 - Abstract #IDWeek2024IDWEEK_2919;
- imipenem/relebactam / Merck (MSD)
Effectiveness of Imipenem-Relebactam for Multidrug-resistant Pseudomonas aeruginosa in Pneumonia and Bloodstream Infections in the United States (MIRAGE) (Halls JK) - Sep 4, 2024 - Abstract #IDWeek2024IDWEEK_2615;
- Epidemiology, clinical, phenotypic, and genotypic characteristics of multidrug, extensive and pan-drug resistant Acinetobacter baumannii from Qatar. (Halls JK) - Sep 4, 2024 - Abstract #IDWeek2024IDWEEK_2062;
- Estimating the Use of Newer Beta-lactam Gram-negative Targeted Antibiotics Across Greater than 700 Hospitals in the United States (Halls JK) - Sep 4, 2024 - Abstract #IDWeek2024IDWEEK_1191;
- Fetroja (cefiderocol) / Shionogi
Cefiderocol Retains in vitro Activity Against Enterobacterales Non-Susceptible to ?-lactam-?-lactamase Inhibitor Combinations (403 A) - Sep 4, 2024 - Abstract #IDWeek2024IDWEEK_929;